





# Safety and Efficacy in HBR preserved at 2 years

**High Bleeding Risk patients:** safety and efficacy benefits of BioFreedom™ Drug-Coated Stent over BMS are preserved up to two years

## ▶ Primary safety endpoint at two years (Cardiac Death, MI and Stent Thrombosis)



## ▶ Primary efficacy endpoint at two years (Clinically driven TLR)



BioFreedom is the only active stent with CE mark for ultra-short 1 month DAPT in High Bleeding Risk (HBR) patients, supported by clinical data from a double-blind randomized controlled trial

**In High Bleeding Risk patients, when compared to BMS, BioFreedom™ and 1 month DAPT is significantly**

▶ **safer**

**Composite of CD, MI and ST**

- ▼ **20% RRR in HBR-General population**
- ▼ **52% RRR in HBR-ACS population**
- ▼ **27% RRR in HBR-Elderly population**

▶ **more effective**

**Id-TLR**

- ▼ **46% RRR in HBR-General population**
- ▼ **59% RRR in HBR-ACS population**
- ▼ **49% RRR in HBR-Elderly population**



**BIOSENSORS**  
INTERNATIONAL™

[www.biosensors.com](http://www.biosensors.com)

**Not available for sale in the United States and certain other countries.**

LEADERS FREE: Two-Year Outcomes of High Bleeding Risk Patients after Polymer-Free Drug-Coated Stents, P. Urban et al. TCT 2016 presentation, JACC online publication  
LEADERS FREE: ACS sub-study: Naber et al. European Heart Journal. First published online: 17th May 2016 DOI:<http://dx.doi.org/10.1093/eurheartj/ehw203>. 11652-000-EN - Rev.01  
LEADERS FREE: Elderly sub-study, M.C. Morice, oral presentation, ESC 2016. 11688-000-EN - Rev.01

BioFreedom is a trademark or registered trademark of Biosensors International Group, Ltd. © 2016 Biosensors International Group, Ltd. All rights reserved.